

RECORD APRIL SALES DRIVE FY26 GUIDANCE UPGRADE

Highlights

- **New monthly sales record in the USA in April 2026, exceeding the record set in March 2026**
- **Group trailing twelve-month sales of US\$22.8 million, up 26% on the prior comparative period**
- **Last twelve-month (LTM) sales (excl. China) of US\$21.6 million at 30 April 2026, with two months of FY26 still to run**
- **FY26 sales (excl. China) guidance upgraded to US\$22–23 million (previously US\$21–22 million)**

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces a new monthly sales record in April 2026, exceeding the record set in March 2026. Trailing twelve-month sales (excl. China) at 30 April 2026 were US\$21.6 million, up 27% on the prior comparative period. Group trailing twelve-month sales were US\$22.8 million, up 26% on the prior comparative period.

	LTM April 25 US\$'000's	LTM April 26 US\$'000's	Growth
USA	13,820	17,758	28%
Germany	1,782	1,851	4%
Sales in Direct markets	15,602	19,608	26%
ROW	1,464	2,038	39%
Sales (Excl China)	17,066	21,646	27%
China	1,070	1,183	11%
Group	18,136	22,829	26%

With two months of FY26 still to run and trading momentum continuing, the Company has upgraded FY26 sales (excl. China) guidance:

Previous sales guidance	Upgraded sales guidance
FY26 sales revenue (excl. China) of between US\$21 million and US\$22 million (A\$30.9 million to A\$32.4 million assuming FX of AUD1.00 = USD0.70 in the last quarter).	FY26 sales revenue (excl. China) of between US\$22 million and US\$23 million (A\$31.4 million to A\$32.8 million assuming FX of AUD1.00 = USD0.70 in the last quarter).

The upgrade follows the Company's first reported positive EBITDA from Operations of US\$138,000 for Q3 FY26, as disclosed in the Quarterly Activities and Cashflow Report on 29 April 2026. For Q3 FY26, each U.S. sales representative delivered annualised revenue of approximately US\$1.6 million on a weighted average basis, with U.S. sales growing at a compound quarterly rate of approximately 6% over the last six quarters. April sales in the U.S. exceeded the record set in March 2026, further extending the trend.

Trading conditions across the U.S. interventional glaucoma sector remain supportive. The U.S. accounts for approximately 53% of global market revenue and is growing at 8% per annum, supported by approximately 32 million cataract procedures performed each year, of which around 1 in 5 patients also have glaucoma. Recent results from listed U.S. interventional glaucoma peers point to sustained end-market demand for canaloplasty and stent-free, tissue-sparing surgical approaches.

– ENDS –

Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.

Company

Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Investors

Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance, a minimally invasive consumable glaucoma surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com